Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Blood AdvancesOpen Access

Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKevin HallALAleksandr LazaryanMLMark van der Laan

Discussion

Loading...

Member takes

Overview

Randomized phase II trial shows belumosudil achieves higher overall response rates in cGVHD patients, suggesting better efficacy than standard treatments.

Key Points

  • Belumosudil improved overall response rate at 6 months by 44.2% compared to best available therapy.
  • Patients treated with belumosudil showed a 61.2% failure-free survival rate after one year, versus 47.8% for best available therapy.
  • Retrospective analysis utilized targeted maximum likelihood estimation to evaluate belumosudil's efficacy against standard treatments.
  • Safety profiles were consistent, with adverse events reported in 27% of belumosudil cases compared to 36% for best available therapy.

Cite This Study

Hall et al. (2025) studied this question.

synapsesocial.com/papers/68bb3ef02b87ece8dc9574a7https://doi.org/10.1182/bloodadvances.2025015832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study2026
  2. 2Transportability to the European population of Efficacy of Belumosudil as Compared with Physician’s Choice of Best Available Therapy for The Treatment of Chronic Graft Versus Host Disease2026
  3. 3Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis2026
  4. 4Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease2025
  5. 5An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD2024 · 26 citations